Despite COVID-19, we are operating at full capacity and all project work is operating as usual.

Clinically predictive preclinical efficacy testing services at your disposal



JUNE 16, 2020

Pharmatest at AACR 2020 virtual meeting

Pharmatest is very excited to participate in AACR virtual meeting II on June 22-24. Registration for this year’s Meeting is free!

Please meet our Team attending AACR 2020 and ready to answer any of your questions regarding our services. Unfortunately, we won't be able to meet you in person but please contact us to arrange a virtual discussion with our experts in oncology.

 

virtual booth_AACR_2020_web2.jpg

 

The following presentations will be available on AACR’s platform on June 22:

Poster 5026: Efficacy of anti-PD-1, IDO inhibitor, chemotherapy and bone-targeting agent on tumor growth in a syngeneic bone metastasis model of triple-negative breast cancer presented by Mari Suominen

Poster 2759: Immune cell killing assay for analyzing the effects of immunomodulating agents in vitro by Jenni Mäki-Jouppila

Poster 1634: Orthotopic and bone metastasis prostate cancer models using the 22Rv1 cell line by Justyna Zdrojewska

 MEET OUR PRESENTERS:

 mari_suominen_round3x3.jpg

Mari Suominen, PhD, Research Director

Mari Suominen joined Pharmatest in 2005. As a Study Director, she is in of charge of customer projects and new model development projects of the cancer field. Previously, she has worked at bone biology department at Schering (currently Bayer), where her responsibility was setting up new models of cancer and skeletal diseases. In her Ph.D. work she studied various therapeutic approaches in experimental mouse models of breast and prostate cancer bone metastasis, including radium-223 (Xofigo). Her whole career has focused on the interaction of bone microenvironment and cancer, and particularly on the development of new therapeutics to treat skeletal metastases.

jenniMJ_round3x3.jpg

Jenni Mäki-Jouppila, PhD, R&D Director

Jenni Mäki-Jouppila joined Pharmatest in 2016 and is working as a Research Director and R&D Director. She has a background in cell and molecular biology. She has graduated as a MSc from the Department of Biology and defended her PhD thesis from the Department of Pharmacology, Drug Development and Therapeutics in the University of Turku. Her previous work has included screening and validation of small molecular compounds and microRNAs targeting mitosis and cell division of cancer cells. Moreover, she has worked in research projects concerning hormonal regulation.

 jz_round3x3.jpg

Justyna Zdrojewska, PhD, Research Director

Justyna Zdrojewska joined Pharmatest in 2017. As a Research Director she is responsible for customer projects and new product development in the field of cancer models. She graduated as MSc from Intercollegiate Faculty of Biotechnology at Gdansk University and further continued her education at Åbo Akademi University, from where she obtained her PhD degree in Cell Biology at the Department of Biosciences.  Her previous work focused on protein interaction and cell migration.

Find our more about our services in oncology here.

REQUEST A VIRTUAL MEETING WITH OUR EXPERTS